盛金丹  /  

—— 硕士生导师 ——

学术型硕导

—— 硕士生招生专业 ——

妇产科学

—— 研究方向 ——

1. 细胞周期与肿瘤的发生 2. 肿瘤联合治疗新靶点的鉴定及临床转化 1. Cell cycle and tumorigenesis 2. Identification of new targets for combination therapy in tumors and clinical translation

—— 学术任职 ——

1、 同济大学附属妇产科医院转化医学研究中心，副研究员 2、 担任cellular oncology等杂志审稿人 3、 日本癌症协会（JCA）会员 4、 美国癌症协会（AACR）会员 1. Associate Researcher, Translational Medicine Research Center, Obstetrics and Gynecology Hospital, Tongji University 2. Act as a reviewer for journals, including Cellular Oncology 3. Member of the Japan Cancer Association (JCA) 4. Member of the American Association for Cancer Research (AACR)

—— 科研项目 ——

(1)国家自然科学基金委员会,青年科学基金项目（C类）[原青年科学基金项目], 82303869, KRAS（G12D）突变通过视神经蛋白（OPTN）负向调控线粒体自噬导致卵巢癌免疫治疗抵抗的机制研究, 2024-01-01 至 2026-12-31, 30万元, 在研, 主持 (2)上海市科技委员会, 上海市2023年度“科技创新行动计划”启明星项目申报指南 / 启明星培育(扬帆专项),23YF1433400,靶向RB1阳性卵巢癌的新型策略研究,2024-04至2026-03,20万元,在研,主持 (3)同济大学，附属妇产科医院,院级课题,2022RC08,CDK4/6抑制剂联合治疗卵巢癌的新型策略研究, 2022-11至2025-11,50万元,在研,主持

—— 学术论文 ——

(1) Jindan Sheng; Susumu Kohno; Nobuhiro Okada; Nobuyuki Okahashi; Kana Teranishi; FumioMatsuda; Hiroshi Shimizu; Paing Linn; Naoko Nagatani; Minako Yamamura; Kenichi Harada; Shin-ichiHorike; Hiroshi Inoue; Seiji Yano; Sharad Kumar; Shunsuke Kitajima; Itsuki Ajioka; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, HEPATOLOGY, 2021, 74(4): 1971-1993 (唯一第一作者 ) (2) Paing Linn; Susumu Kohno; Jindan Sheng; Nilakshi Kulathunga; Hai Yu; Zhiheng Zhang;Dominic Voon; Yoshihiro Watanabe; Chiaki Takahashi ; Targeting RB1 Loss in Cancers, cancers,2021, 13(15): 3737 (3) Mingjun Ma; Chao Wang; Meixuan Wu; Sijia Gu; Jiani Yang; Yue Zhang; Shanshan Cheng;Shilin Xu; Minghai Zhang; Yongsong Wu; Yaqian Zhao; Xiu Tian; Dominic Chih-Cheng Voon; Chiaki Takahashi; Jindan Sheng; Yu Wang ; CSGALNACT2 restricts ovarian cancer migration and invasion by modulating MAPK/ERK pathway through DUSP1, Cellular Oncology, 2023, 903(9): 13402 ( 共同通讯作者 ) (4) Xiaomei Luo; Yingjie Wang; Hao Zhang; Guangquan Chen; Jindan Sheng; Xiu Tian; Renhao Xue;Yu Wang ; Identification of a Prognostic Signature for Ovarian Cancer Based on Ubiquitin-Related Genes Suggesting a Potential Role for FBXO9,Biomolecules, 2023, 13(12): 1724 (5) Jiani Yang; Chao Wang; Yue Zhang; Shanshan Cheng; Meixuan Wu; Sijia Gu; Shilin Xu;Yongsong Wu; Jindan Sheng; Dominic Chih-Cheng Voon; Yu Wang ; Clinical significance and immune infiltration analyses of a novel coagulation-related signature in ovarian cancer, Cancer Cell International, 2023, 23(1) (6) Meixuan Wu, Sijia Gu, Jiani Yang, Yaqian Zhao, Jindan Sheng, Shanshan Cheng, Shilin Xu, Yongsong Wu, Mingjun Ma, Xiaomei Luo, Hao Zhang, Yu Wang, Aimin Zhao; Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer, BMC Cancer,2024,24(1):267. (7) Yuanyuan Zhang, Susumu Kohno, Keqi Gao, Mahadi Hasan, Tomohisa Baba Zixue Zhang, Nao Sankoda, Hai Yu, Junjian Pan, Noriko Gotoh, Makoto Nakanishi , Yasuhiro Yamada, Jindan Sheng, Takiko Daikoku, Yoshikazu Johmuraand Chiaki Takahashi; Deprivation of EGFR signal causes senolysis in PDAC with CDK4/6inhibition,Gastroenterology,2025, under revision. (8) Chen Chu Shanshan Zheng, Ning Mitchell, Zheqi Li Xiaowei Wu, Tian Zhang, Fabin Dang, Wojciech Michowski, Miranda L. Xu, Aleksandra Kolodziejczyk, Joao Paulo, Xixi Zhang, Krzysztof Kotowski, Diego Martinez-Alonso, Jane A. Kirby, Finn Groezinger, Yubin Zhou, Miao He, Yoshinaga Ito, Anushree C. Gulvady, Pierre Foidart, Jun Nishida, Xiaohan Ning, Yu Zhou, Jindan Sheng, Samanta Sharma, Jan M. Suski, Anne Fassl, Yan Geng, Wenyi Wei, Steven P Gygi, Kornelia Polyak, Kai W Wucherpfennig, Piotr Sicinski, CDK2 kinase inhibition promotes PD-L1 transcription through BRD4 and synergizes with immune checkpoint blockade,Cell, 2025, under revision.

—— 其他成果 ——

一：专利 (1) 高橋 智聡; 河野 晋; 盛金丹，ＲＢ１陽性癌の治療用医薬組成物及びキット, 2020-10-28, 日本,特願2020-180429 (药物发明专利)。 (2) 王育; 盛金丹; 张越; 汪超 ; 一种治疗CCNE1异常扩增型卵巢癌的药物组合物及其应用, 2023-12-6,中国, 202311658341.3 (药物发明专利)。 (3) 王育; 盛金丹; 吴美璇; 顾思佳；一种治疗RB1阳性的卵巢癌的组合药物及其应用, 2023-6-6, 中国, 202310374279.9 (药物发明专利)。 (4) 王育; 盛金丹; 顾思佳; 吴美璇；一种治疗kras突变的卵巢癌的组合药物及其应用, 2023-5-31,中国, 202310374305.8 (药物发明专利)。 二：科研奖励 (1) Jindan Sheng; A targetable NF-κB−LCN2 axis controls liver tumorigenesis, 中国驻日本大使馆, 国际学术奖, 2022年国家自费留学生奖学金B类 (2)盛金丹; 肝細胞がんの分子機序解明と新規治療法開発, 2021年度日本学政育志赏提名。 (3)盛金丹；2021年度日本金泽大学高安奖 (4)盛金丹；2021年度日本金泽大学校长奖 (5)盛金丹；2021年度日本金泽大学医学院代表奖 三：学术会议 (1) Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 43rd Annual Meeting of the Molecular Biology Society of Japan (MBSJ2020 Online) , 线上, 2020-12-2至2020-12-4 (会议报告) (2) Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, 2021 the Japanese Society of Medical Oncology Annual Meeting (JSMO2021), 线上, 2021-2-18至2021-2-21 (会议报告) (3) Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, AACR ANNUAL MEETING 2021 2021/4/10-2021/4/15, 线上, 2021-4-10至2021-4-15 (会议报告) (4) Jindan Sheng; Chiaki Takahashi ; Treatment of Retinoblastoma 1–Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy, The 80th Annual Meeting of the Japanese Cancer Association 2021/09/30-2021/10/02, 线上, 2021-9-30至2021-10-2 (会议报告) (5)Jindan sheng ；2024-5-7至2024-5-9,MGH Molecular Biology & HMS Genetics, Omni Mount Washington Hotel Bretton Woods, NH(参加学术会议) (6) Jindan sheng；2024-3-1至2024-3-1, 参加Cancer Biology Retreat 2024, Broad Institute of MIT and Harvard, (参加学术会议)